These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
184 related articles for article (PubMed ID: 35418351)
1. Current Status of CPX-351 Therapy in Acute Myeloid Leukemia and Myelodysplastic Syndrome. Alotaibi S; Niederwieser D; Ahmed SO; Sanz J; Mohty M; Aljurf M Clin Lymphoma Myeloma Leuk; 2022 Aug; 22(8):575-580. PubMed ID: 35418351 [TBL] [Abstract][Full Text] [Related]
2. CPX-351 (vyxeos) in AML. Alfayez M; Kantarjian H; Kadia T; Ravandi-Kashani F; Daver N Leuk Lymphoma; 2020 Feb; 61(2):288-297. PubMed ID: 31547736 [TBL] [Abstract][Full Text] [Related]
3. CPX-351 daunorubicin-cytarabine liposome: a novel formulation to treat patients with newly diagnosed secondary acute myeloid leukemia. Cafaro A; Giannini MB; Silimbani P; Cangini D; Masini C; Ghelli Luserna Di Rorà A; Simonetti G; Martinelli G; Cerchione C Minerva Med; 2020 Oct; 111(5):455-466. PubMed ID: 32955826 [TBL] [Abstract][Full Text] [Related]
4. Liposomal encapsulated cytarabine and daunorubicin (CPX-351) for older patients with acute myeloid leukemia. Asghari H; Lancet J Leuk Lymphoma; 2020 Jun; 61(6):1305-1312. PubMed ID: 32037927 [TBL] [Abstract][Full Text] [Related]
5. CPX-351: changing the landscape of treatment for patients with secondary acute myeloid leukemia. Talati C; Lancet JE Future Oncol; 2018 May; 14(12):1147-1154. PubMed ID: 29378418 [TBL] [Abstract][Full Text] [Related]
6. First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia. Feldman EJ; Lancet JE; Kolitz JE; Ritchie EK; Roboz GJ; List AF; Allen SL; Asatiani E; Mayer LD; Swenson C; Louie AC J Clin Oncol; 2011 Mar; 29(8):979-85. PubMed ID: 21282541 [TBL] [Abstract][Full Text] [Related]
7. AML with Myelodysplasia-Related Changes: Development, Challenges, and Treatment Advances. Koenig KL; Sahasrabudhe KD; Sigmund AM; Bhatnagar B Genes (Basel); 2020 Jul; 11(8):. PubMed ID: 32722092 [TBL] [Abstract][Full Text] [Related]
8. Daunorubicin-cytarabine liposome (CPX-351) in the management of newly diagnosed secondary AML: A new twist on an old cocktail. Maakaron JE; Mims AS Best Pract Res Clin Haematol; 2019 Jun; 32(2):127-133. PubMed ID: 31203994 [TBL] [Abstract][Full Text] [Related]
9. Quality-adjusted Time Without Symptoms of disease or Toxicity (Q-TWiST) analysis of CPX-351 versus 7 + 3 in older adults with newly diagnosed high-risk/secondary AML. Cortes JE; Lin TL; Uy GL; Ryan RJ; Faderl S; Lancet JE J Hematol Oncol; 2021 Jul; 14(1):110. PubMed ID: 34256819 [TBL] [Abstract][Full Text] [Related]
10. Daunorubicin and Cytarabine Liposome in Newly Diagnosed Therapy-Related Acute Myeloid Leukemia (AML) or AML With Myelodysplasia-Related Changes. Kim M; Williams S Ann Pharmacother; 2018 Aug; 52(8):792-800. PubMed ID: 29532662 [TBL] [Abstract][Full Text] [Related]
11. EMA Review of Daunorubicin and Cytarabine Encapsulated in Liposomes (Vyxeos, CPX-351) for the Treatment of Adults with Newly Diagnosed, Therapy-Related Acute Myeloid Leukemia or Acute Myeloid Leukemia with Myelodysplasia-Related Changes. Tzogani K; Penttilä K; Lapveteläinen T; Hemmings R; Koenig J; Freire J; Márcia S; Cole S; Coppola P; Flores B; Barbachano Y; Roige SD; Pignatti F Oncologist; 2020 Sep; 25(9):e1414-e1420. PubMed ID: 32282100 [TBL] [Abstract][Full Text] [Related]
12. Real-world experience with CPX-351 in high-risk acute myeloid leukemia. Lemoli RM; Montesinos P; Jain A Crit Rev Oncol Hematol; 2023 May; 185():103984. PubMed ID: 37028531 [TBL] [Abstract][Full Text] [Related]
13. CREST-UK: Real-world effectiveness, safety and outpatient delivery of CPX-351 for first-line treatment of newly diagnosed therapy-related AML and AML with myelodysplasia-related changes in the UK. Mehta P; Campbell V; Maddox J; Floisand Y; Kalakonda AJM; O'Nions J; Coats T; Nagumantry S; Hodgson K; Whitmill R; Amott I; Flynn G; Taussig D; Zhao R; Cunningham N; Roset M; Cuadras D; Medalla G; Kuter H; Park S; Legg A; Khan AB Br J Haematol; 2024 Oct; 205(4):1326-1336. PubMed ID: 38977430 [TBL] [Abstract][Full Text] [Related]
14. Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML. Lancet JE; Cortes JE; Hogge DE; Tallman MS; Kovacsovics TJ; Damon LE; Komrokji R; Solomon SR; Kolitz JE; Cooper M; Yeager AM; Louie AC; Feldman EJ Blood; 2014 May; 123(21):3239-46. PubMed ID: 24687088 [TBL] [Abstract][Full Text] [Related]
15. A phase 1/2 study of NS-87/CPX-351 (cytarabine and daunorubicin liposome) in Japanese patients with high-risk acute myeloid leukemia. Usuki K; Miyamoto T; Yamauchi T; Ando K; Ogawa Y; Onozawa M; Yamauchi T; Kiyoi H; Yokota A; Ikezoe T; Katsuoka Y; Takada S; Aotsuka N; Morita Y; Ishikawa T; Asada N; Ota S; Dohi A; Morimoto K; Imai S; Kishimoto U; Akashi K; Miyazaki Y; Int J Hematol; 2024 Jun; 119(6):647-659. PubMed ID: 38532078 [TBL] [Abstract][Full Text] [Related]
16. Diagnosis and Treatment of Patients With Acute Myeloid Leukemia With Myelodysplasia-Related Changes (AML-MRC). Arber DA; Erba HP Am J Clin Pathol; 2020 Nov; 154(6):731-741. PubMed ID: 32864703 [TBL] [Abstract][Full Text] [Related]
17. CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia. Lancet JE; Uy GL; Cortes JE; Newell LF; Lin TL; Ritchie EK; Stuart RK; Strickland SA; Hogge D; Solomon SR; Stone RM; Bixby DL; Kolitz JE; Schiller GJ; Wieduwilt MJ; Ryan DH; Hoering A; Banerjee K; Chiarella M; Louie AC; Medeiros BC J Clin Oncol; 2018 Sep; 36(26):2684-2692. PubMed ID: 30024784 [TBL] [Abstract][Full Text] [Related]
18. Reformulating acute myeloid leukemia: liposomal cytarabine and daunorubicin (CPX-351) as an emerging therapy for secondary AML. Chen EC; Fathi AT; Brunner AM Onco Targets Ther; 2018; 11():3425-3434. PubMed ID: 29928134 [TBL] [Abstract][Full Text] [Related]
19. CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial. Lancet JE; Uy GL; Newell LF; Lin TL; Ritchie EK; Stuart RK; Strickland SA; Hogge D; Solomon SR; Bixby DL; Kolitz JE; Schiller GJ; Wieduwilt MJ; Ryan DH; Faderl S; Cortes JE Lancet Haematol; 2021 Jul; 8(7):e481-e491. PubMed ID: 34171279 [TBL] [Abstract][Full Text] [Related]
20. Multicenter comparison of high-dose cytarabine-based regimens versus liposomal daunorubicin and cytarabine (CPX-351) in patients with secondary acute myeloid leukemia. Benitez LL; Perissinotti AJ; Rausch CR; Klaus J; Clark SM; Filtz M; Ratermann K; Treptow C; Griffin S; Olson M; Crain M; Kadia T; Pettit K; Burke PW; Bixby DL; Marini BL Leuk Lymphoma; 2021 Sep; 62(9):2184-2192. PubMed ID: 33830856 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]